SCHEMBL29205308

SCHEMBL29205308

Cc1ncn(-c2ccc(C=O)cc2)c1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.57
PDE3B Q13370 1/20 0.50
PDE3A Q14432 1/20 0.50
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
HPGD P15428 1/20 0.47
HIF1A Q16665 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CYP2A6 P11509 1/20 0.43
KDM4E B2RXH2 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KCNJ1 P48048 1/20 0.41
TRIM24 O15164 1/20 0.40
TRIM33 Q9UPN9 1/20 0.40
MAPK1 P28482 1/20 0.40
ALDH5A1 P51649 1/20 0.39
ABAT P80404 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
BRD4 O60885 1/20 0.38
FGFR1 P11362 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9288138 0.80 ALDH1A1 (0.53) ALDH1A1PDE3BPDE3ACYP1A2CYP2D6
SCHEMBL30899605 0.80 KCNJ1 (0.49) ALDH1A1PDE3BPDE3ACYP1A2CYP2D6
SCHEMBL20057789 0.77 ALDH1A1 (0.49) ALDH1A1CYP2A6KDM4ESMN1; SMN2FGFR1
SCHEMBL22143673 0.77 MKNK1 (0.52) ALDH1A1PDE3BPDE3ACYP1A2CYP2D6
SCHEMBL19214262 0.77 ALDH1A1 (0.50) ALDH1A1PDE3BPDE3ACYP1A2CYP2D6
SCHEMBL20168395 0.76 ALDH1A1 (0.42) ALDH1A1PDE3BPDE3ACYP1A2CYP2D6
SCHEMBL22510633 0.76 ALDH1A1 (0.63) ALDH1A1CYP1A2CYP2D6HPGDHIF1A
SCHEMBL24784278 0.74 ALDH1A1 (0.47) ALDH1A1PDE3BPDE3ACYP1A2CYP2D6
SCHEMBL9259435 0.74 ALDH1A1 (0.47) ALDH1A1PDE3BPDE3ACYP1A2CYP2D6
SCHEMBL4188670 0.73 ALDH1A1 (1.00) ALDH1A1PDE3BPDE3ACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240398783-A1 Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof GISMO THERAPEUTICS, INC. 2024-12-05 US disclosed
EP-4398902-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF AMYLOID PEPTIDE INTERACTIONS WITH GLYCOSAMINOGLYCANS, METHODS OF TREATMENT, AND USE THEREOF Gismo Therapeutics, Inc. (US) 2024-07-17 EP disclosed
CN-117999075-A Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interaction with glycosaminoglycans, methods of treatment, and uses thereof 吉斯莫治疗股份有限公司 2024-05-07 CN disclosed
WO-2023038876-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF AMYLOID PEPTIDE INTERACTIONS WITH GLYCOSAMINOGLYCANS, METHODS OF TREATMENT, AND USE THEREOF GISMO THERAPEUTICS, INC. (US) 2023-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240398783-A1 Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof PRNP, GBA1, GBA3 ALDH1A1 3486/4885PDE3B 854/4885PDE3A 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.